US 7,396,541 B2 | ||
Heparin prodrugs and drug delivery stents formed therefrom | ||
Syed Faiyaz Ahmed Hossainy, Fremont, Calif. (US); and Ni Ding, San Jose, Calif. (US) | ||
Assigned to Advanced Cardiovascular Systems, Inc., Santa Clara, Calif. (US) | ||
Filed on Sep. 15, 2005, as Appl. No. 11/228,420. | ||
Application 11/228420 is a division of application No. 10/871658, filed on Jun. 18, 2004. | ||
Prior Publication US 2006/0014720 A1, Jan. 19, 2006 | ||
Int. Cl. A61F 2/00 (2006.01) |
U.S. Cl. 424—423 | 15 Claims |
1. A medical device comprising as a coating a prodrug, the prodrug comprising a drug, heparin, and a polymer,
wherein the heparin is linked to the polymer;
wherein the drug is linked to the heparin or the polymer; and
wherein the polymer is poly(L-lysine-co-ethylene glycol) (PLL-co-PEG), poly(L-lysine-co-hyaluronic acid) (PLL-co-HA), poly(L-lysine-co-phosphoryl
choline) (PLL-co-PC), poly(L-lysine-co-PVP), poly(ethylimine-co-ethylene glycol) (PEI-co-PEG), poly(ethylimine-co-hyaluronic
acid) (PEI-co-HA), poly(ethylimine-co-phosphoryl choline) (PEI-co-PC), poly(ethylimine-co-vinylpyrrolidone) (PEI-co-PVP),
poly(L-lysine-g-ethylene glycol) (PLL-g-PEG), poly(L-lysine-g-hyaluronic acid) (PLL-g-HA), poly(L-lysine-g-phosphoryl choline)
(PLL-g-PC), poly(L-lysine-g-PVP), poly(ethylimine-g-ethylene glycol) (PEI-g-PEG), poly(ethylimine-g-hyaluronic acid) (PEI-g-HA),
poly(ethylimine-g-phosphoryl choline) (PEI-g-PC), and poly(ethylimine-g-vinylpyrrolidone) (PEI-g-PVP).
|